LAVA Therapeutics N.V. (LVTX)
0.97
-0.01 (-1.02%)
At close: Jan 15, 2025, 1:52 PM
undefined% (undefined)
| Bid | 0.96 |
| Market Cap | 25.39M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.99 |
| Volume | 16,523 |
| Avg. Volume (20D) | 119,432 |
| Open | 1.00 |
| Previous Close | 0.98 |
| Day's Range | 0.95 - 1.00 |
| 52-Week Range | 0.88 - 6.47 |
| Beta | undefined |
About LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 37
Stock Exchange NASDAQ
Ticker Symbol LVTX
Website https://www.lavatherapeutics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 107.15% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
LAVA Therapeutics N.V. is scheduled to release its earnings on Mar 19, 2025,
before market opens.
Analysts project revenue of $2.40M, reflecting a 579.89% YoY growth and earnings per share of -0.27, making a 12.50% increase YoY.
Analysts project revenue of $2.40M, reflecting a 579.89% YoY growth and earnings per share of -0.27, making a 12.50% increase YoY.
1 month ago ·
Source
-23.56%
LAVA Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
5 months ago · 247wallst.com
4 Stocks Under $5 To Buy NowAre you looking for stocks to buy with low price tags?
